Product Introduction Copy (Marketing Copy)
ZFirst HCY Assay Kit: Quantum Dot Technology, Precise Early Warning for Cardiovascular and Cerebrovascular Risks
The increase in homocysteine (Homocysteine, HCY) levels is recognized as an independent risk factor for cardiovascular and cerebrovascular diseases. ZFirst employs the innovative quantum dot immunofluorescence method (QD-FIA) to achieve rapid and precise quantitative determination of serum HCY levels. It is an important tool for screening H-type hypertension, preventing strokes, and assessing folate/vitamin B12 deficiencies. 

Core Advantages (Why ZFirst HCY)
Quantum dot-driven outstanding sensitivity: Leveraging the physical characteristics of quantum dots, which feature narrow emission and extremely strong light stability, the ZFirst kit exhibits excellent linear relationships within the critical clinical threshold range, with detection accuracy comparable to that of large-scale fully automatic biochemical analyzers in laboratories.
A powerful tool for H-type hypertension screening: Targeting the globally prevalent H-type hypertension (hypertension combined with high HCY), ZFirst offers an efficient on-site testing and immediate result delivery solution, assisting primary medical institutions in achieving stratified management of hypertension.
POCT rapid quantitative report: Compatible with the ZFirst quantum dot fluorescence analyzer, the process from sample processing to quantitative result output takes only 15 minutes. The operation process is extremely simple, and high-quality testing can be completed without a professional laboratory background.
Strong anti-interference ability: Quantum dot technology can effectively shield the interference of background fluorescence in blood samples, ensuring excellent consistency and repeatability (CV < 10%) in serum and plasma samples.
Compliant quality, authoritative certification: Possessing a national medical device registration certificate (Lu Jian Zun Zhan Jian 20222400188), the production process strictly follows ISO 13485 standards, ensuring that global customers can obtain consistent export-level quality.

Product Specifications

Product Short Description

The ZFirst Homocysteine Test Kit (HCY Assay Kit) supplied by Beijing Jiachuang Jiuhe Global Trade Co., Ltd utilizes advanced Quantum Dot Fluorescence Immunoassay (QD-FIA) technology to quantitatively measure total homocysteine concentrations in human serum and plasma. Elevated serum homocysteine is a recognized independent risk factor for arterial thrombosis, stroke, and vascular diseases. As an essential diagnostic reagent for Cardiovascular Risk Assessment, this HCY QD-FIA Test delivers fast quantitative results in just 15 minutes. Combining high optical precision via Quantum Dot Immunoassay mechanisms with automated ID chip batch calibration, the ZFirst Homocysteine Test Kit provides healthcare institutions with an efficient point-of-care testing solution.

Detailed Product Description

Beijing Jiachuang Jiuhe Global Trade Co., Ltd presents the ZFirst Homocysteine Test Kit, an advanced diagnostic reagent engineered for fast clinical screening and quantitative assessment of vascular risk profile. Homocysteine is a sulfur-containing amino acid formed during the metabolic demethylation of methionine. Hyperhomocysteinemia, characterized by abnormally elevated circulatory homocysteine, causes endothelial cell dysfunction, smooth muscle proliferation, and enhanced thrombogenesis. Utilizing a high-precision Homocysteine Test Kit allows clinicians to evaluate metabolic dysfunction, assess stroke risk, and initiate early targeted clinical interventions.

The ZFirst HCY QD-FIA Test incorporates high-performance semiconductor quantum dot nanostructures paired with modern immunofluorescence principles. Conventional enzymatic methods or organic dye immunodiagnostics often face matrix interference, narrow dynamic ranges, and signal degradation over time. The ZFirst HCY Assay Kit overcomes these analytical limitations by leveraging narrow emission spectra, high quantum yield, and superior photostability inherent to Quantum Dot Immunoassay chemistry. This ensures excellent linear performance across critical clinical decision thresholds without background signal interference.

Engineered to streamline point-of-care testing and central laboratory operations, the ZFirst Homocysteine Test Kit simplifies pretreatment through a dedicated sample diluent. This specialized diluent releases bound homocysteine from carrier proteins in serum or plasma, maximizing analytical recovery rates. Paired with compatible ZFirst quantum dot fluorescence analyzers, the ZFirst HCY Assay Kit yields dependable quantitative reports in 15 minutes, empowering primary care facilities, cardiology departments, and neurology units to execute rapid Cardiovascular Risk Assessment routines.

Core Features & Key Advantages

• Quantum Dot Immunoassay Precision: Powered by semiconductor quantum dot nanomaterials, the ZFirst Homocysteine Test Kit delivers high signal brightness, high signal-to-noise ratios, and reliable quantitative precision comparable to large central laboratory biochemical analyzers.

• Essential Cardiovascular Risk Assessment Tool: Tailored for early detection, the ZFirst HCY QD-FIA Test aids in screening H-type hypertension (hypertension paired with elevated homocysteine levels), stroke prevention, and metabolic risk stratification.

• Rapid POCT Quantitative Results: Compatible with ZFirst series quantum dot fluorescence analyzers, the ZFirst HCY Assay Kit outputs accurate quantitative values within 15 minutes, significantly accelerating clinical decision-making.

• Superior Anti-Interference Capacity: Quantum dot photophysics effectively shield against background biological autofluorescence in whole serum and plasma, maintaining a coefficient of variation below 10 percent.

• Integrated Quality Assurance: Each 25-test box features individually sealed cassettes, dedicated sample diluent, and an independent ID chip for automatic batch calibration, guaranteeing strict regulatory compliance and reproducible data.

In-Depth Technology & Analytical Advantage

The analytical excellence of the ZFirst Homocysteine Test Kit relies on the physical properties of semiconductor quantum dots. Unlike traditional organic fluorophores that suffer from rapid photobleaching and broad emission curves, quantum dots feature broad excitation bandwidths paired with narrow, symmetrical emission peaks. This physical property prevents optical crosstalk, enabling clear signal separation during light emission reading.

When executing an HCY Assay Kit, converting protein-bound homocysteine into measurable free forms is crucial for accurate quantitative assessment. The dedicated sample diluent supplied in the ZFirst Homocysteine Test Kit liberates target molecules efficiently. Furthermore, because whole serum and plasma matrices contain biological components that cause autofluorescence, the high quantum yield of the ZFirst Quantum Dot Immunoassay overcomes sample background noise. Coupled with automated curve fitting via the ZFirst ID chip system, the ZFirst HCY QD-FIA Test provides reliable analytical sensitivity across the entire clinical measurement range.

Clinical Applications

• H-Type Hypertension Management: Utilizing the ZFirst Homocysteine Test Kit enables early identification of H-type hypertension, facilitating targeted dual-therapy with antihypertensives and folic acid supplements.

• Cardiovascular Risk Assessment: Serves as an independent biomarker assay to evaluate atherothrombotic risk, coronary artery disease progression, and peripheral vascular disease.

• Cerebrovascular Disease & Stroke Screening: Applying the ZFirst HCY Assay Kit helps neurologists identify patients at elevated risk for ischemic stroke and cognitive decline.

• Obstetric & Perinatal Risk Monitoring: Monitoring homocysteine levels during early pregnancy assists in identifying risks associated with neural tube defects, preeclampsia, and recurrent pregnancy loss.

Commercial Value for B2B Healthcare Partners

Partnering with Beijing Jiachuang Jiuhe Global Trade Co., Ltd to distribute the ZFirst Homocysteine Test Kit brings significant operational, economic, and strategic advantages to hospital procurement departments, commercial laboratories, and medical device distributors:

1. High Market Demand: Vascular diseases remain a leading cause of global mortality. Providing a rapid, reliable HCY QD-FIA Test allows distributors to meet growing global demand for point-of-care Cardiovascular Risk Assessment tools.

2. Optimized Logistics & Storage: Featuring a broad storage range of 2°C to 30°C and an 18-month shelf life, the ZFirst Homocysteine Test Kit simplifies cold-chain distribution logistics and reduces warehouse overhead.

3. High Operational Efficiency: With a quick 15-minute testing time, clinical laboratories using the ZFirst HCY Assay Kit can increase daily sample throughput without increasing operational staffing costs.

4. Authoritative Compliance & Support: Distributed by Beijing Jiachuang Jiuhe Global Trade Co., Ltd under ISO 13485 standards and certified regulatory registration, partners receive complete export documentation, technical training, and reliable supply chain support.

Frequently Asked Questions (FAQ)

Q1: Why is an HCY Assay Kit essential for H-type hypertension screening?
A: Patients with H-type hypertension (hypertension combined with elevated homocysteine levels) face a significantly higher risk of stroke. Measuring levels with a Homocysteine Test Kit allows clinicians to initiate early targeted folic acid therapy alongside standard blood pressure management.

Q2: How does Quantum Dot Immunoassay technology benefit the ZFirst HCY QD-FIA Test?
A: Quantum Dot Immunoassay technology uses bright semiconductor nanocrystals that resist photobleaching and emit narrow light spectra. This eliminates background signal interference from blood matrix components, ensuring quantitative precision comparable to central laboratory instruments.

Q3: What sample matrices are suitable for the ZFirst Homocysteine Test Kit?
A: The ZFirst Homocysteine Test Kit is validated for both human serum and plasma samples. Each kit includes dedicated sample diluent designed to treat samples and release bound homocysteine for optimal assay recovery.